在染色体4q2525上,针对心房动的独立敏感性标志物
Steven A Lubitz1, Moritz F Sinner, Kathryn L Lunetta
1Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA 02114, USA.
Circulation
|August 25, 2010
概括
染色体4q25上的遗传变异与心房动 (AF) 有关. 这项研究在这个位置发现了两个新的AF易感信号,改善了风险预测.
科学领域:
- 遗传学 是一个遗传学.
- 心血管疾病 心血管疾病
背景情况:
- 染色体4q25上的遗传变异是已知的心房动 (AF) 的风险因素.
- 以前的研究表明,在这个位置可能存在多个易感信号.
研究的目的:
- 调查4q25心房的位置是否存在多个易感信号.
- 为了确定与AF风险相关的新型遗传标记.
主要方法:
- 在发现队列中以4q25的基因型确定了34个单核酸多态 (SNP).
- 在大型独立队列中重复发现,包括元分析.
- 使用SNP标记不同的AF信号构建了一个多标记器风险评分.
主要成果:
- 已知的SNP rs2200733显示与AF有很强的关联.
- 在对rs2200733.3进行调整后,确定了两个新的AF易感信号,标记为rs17570669和rs3853445.
- 在这三种信号中,风险等位基因数量的增加与AF风险的增加有关.
结论:
- 在染色体4q25.25上发现了两种新的心房动易感信号.
- 在4q25的多个信号增强了对AF风险增加的个体的识别.
- 这些信号可能会精确地确定AF病变发生过程中至关重要的调节元素.
更多相关视频
相关概念视频
Single Nucleotide Polymorphisms-SNPs
14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
1.2K
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.2K


